Oki T, Yoshimoto A, Matsuzawa Y, Takeuchi T, Umezawa H
J Antibiot (Tokyo). 1980 Nov;33(11):1331-40. doi: 10.7164/antibiotics.33.1331.
An aclacinomycin-negative mutant strain KE303 which required aklavinone aglycone for the production of anthracycline antibiotics was derived from Streptomyces galilaeus, and employed for the glycosidation of various anthracyclinones. epsilon- gamma- and beta-Rhodomycinones, epsilon-isorhodomycinone, epsilon- and beta-pyrromycinones and chemically modified aklavinones were found to be glycosidated to the biologically active anthracyclines, when they were fed to the growing culture. However, the feeding of daunomycinone, 13-deoxydaunomycinone, adriamycinone and steffimycinone did not yield any glycoside. The bioconversion of presumptive precursor glycosides revealed that aclacinomycin A is biosynthesized by the step-wise glycosidation from aklavinone vai aklavin and MA144 S1.
一种阿克拉霉素阴性突变菌株KE303,它需要阿克拉维酮苷元来生产蒽环类抗生素,该菌株源自加利利链霉菌,并用于各种蒽环酮的糖基化反应。当向生长的培养物中添加ε-、γ-和β-玫瑰霉素酮、ε-异玫瑰霉素酮、ε-和β-吡咯霉素酮以及化学修饰的阿克拉维酮时,发现它们被糖基化为具有生物活性的蒽环类药物。然而,添加柔红霉素酮、13-脱氧柔红霉素酮、阿霉素酮和司替霉素酮并未产生任何糖苷。推测的前体糖苷的生物转化表明,阿克拉霉素A是通过从阿克拉维酮经阿克拉维及MA144 S1逐步糖基化生物合成的。